Pacira BioSciences, Inc. (PCRX)
Solvency ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 2.00 | 2.03 | 1.87 | 1.77 | 1.81 | 1.85 | 1.91 | 1.98 | 2.17 | 2.25 | 2.29 | 2.67 | 2.84 | 1.89 | 1.93 | 1.98 | 2.06 | 2.09 | 2.23 | 2.20 |
Pacira BioSciences, Inc. has shown strong solvency positions based on its solvency ratios over the analyzed period. The Debt-to-assets ratio has consistently been at 0.00, indicating that the company has not relied heavily on debt to finance its assets.
Similarly, the Debt-to-capital ratio has also remained at 0.00 throughout the period, suggesting that the company has not been heavily reliant on debt to fund its operations or investments relative to its capital structure.
The Debt-to-equity ratio has also consistently been at 0.00, indicating that Pacira BioSciences has maintained a healthy balance between debt and equity in its capital structure.
The Financial leverage ratio, which measures the extent to which a company is using debt to finance its operations, has shown some fluctuations but generally remained within a reasonable range. The decreasing trend from 2020 to 2023, followed by a slight increase in 2024, may indicate that the company has been managing its debt levels effectively.
Overall, based on the solvency ratios, Pacira BioSciences appears to have a strong financial position with minimal reliance on debt to support its operations and investments.
Coverage ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | -4.29 | -3.88 | 7.73 | 6.77 | 2.92 | 0.73 | 0.63 | 0.29 | 1.34 | 2.87 | 3.35 | 4.12 | 4.48 | 4.32 | 3.87 | 2.79 | 2.48 | 2.14 | 1.46 | 1.79 |
The interest coverage ratio of Pacira BioSciences, Inc. has exhibited fluctuations over the period depicted in the data.
The trend shows a gradual increase from March 31, 2020 (1.79) to June 30, 2021 (3.87), indicating the company's ability to cover its interest expenses improved during this period.
From June 30, 2021 to June 30, 2022, there was a slight decrease in the interest coverage ratio, which could suggest a relative weakening in the company's ability to cover its interest payments.
A significant drop is observed from March 31, 2024 (6.77) to September 30, 2024 (-3.88), and December 31, 2024 (-4.29), signaling potential financial distress as the company's earnings may not be sufficient to cover its interest obligations during these periods.
Overall, fluctuations in the interest coverage ratio highlight the importance of monitoring a company's ability to meet its interest payments from its operating income.